A Phase 2/3 interventional study of 30 minute photoactivation of riboflavin 0.1% and 10 minute photoactivation of riboflavin 0.1% in Corneal Neovascularization, sponsored by Price Vision Group. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
27 studies on the registry are indexed under Corneal Neovascularization; 4 are open to participants now.
This study's planned enrollment of 138 is above the median of 24 across 22 interventional studies indexed under Corneal Neovascularization.
Browse Corneal Neovascularization studies →Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
Combination Product: 30 minute photoactivation of riboflavin 0.1%
photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
Combination Product: 10 minute photoactivation of riboflavin 0.1%
Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
corneal neovascularization as a proportion of the total corneal area
the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.
Time frame: 6 months
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Price Vision Group